At the recent ASGCT 2025 Annual Meeting, GenAssist first showcased its cutting-edge HOPE (Human Originated Peptide Evolution) AAV evolution platform. This platform displays extremely enormous human genomic sequences （3B nt）on AAV via GenAssist’s proprietary primer library. HOPE technology enables the generation of about 10 billion random peptide libraries and more than 1 million AAV sequences, which facilitates the possibility of any tissue-specific AAV capsids through appropriate screening system. Until now, GenAssist successfully identified a novel AAV capsid (8V1-3) with high muscle specificity and liver detargeting. The platform has also achieved significant progress in developing AAVs for CNS, kidneys, lungs, and PBMCs. This project has been supported by 2023 National Innovation Center Grant.
Currently, GenAssist is advancing its DMD pipeline with in vivo proof-of- concept studies and expanding development of gene therapy products targeting diverse tissues. We are actively seeking global partners to collaborate on custom AAV capsid screening or licensing opportunities based on the HOPE platform.
If you are interested in collaborating or learning more, please contact us at:
Email: xinya@genassisttx.com
Let’s innovate together for a brighter future in gene therapy!
